Thierry Conroy, MD, on Pancreatic Cancer: Results From the PRODIGE 24 Trial
2018 ASCO Annual MeetingThierry Conroy, MD, of the Institut de Cancérologie de Lorraine, discusses phase III study findings on adjuvant mFOLFIRINOX vs gemcitabine in patients with resected pancreatic ductal adenocarcinomas (Abstract LBA4001).
Related Videos
Toni K. Choueiri, MD, and Lauren C. Harshman, MD on RCC: Results From the PROSPER Trial
Toni K. Choueiri, MD, and Lauren C. Harshman, MD, both of Dana-Farber Cancer Institute, discuss phase III study findings on perioperative nivolumab vs observation ...
Jun J. Mao, MD, MSCE, on Insomnia in Cancer Survivors: Trial Results
Jun J. Mao, MD, MSCE, of Memorial Sloan Kettering Cancer Center, discusses study findings on the effect of acupuncture vs cognitive behavior therapy in cancer survivors experiencin...
Meletios A. Dimopoulos, MD, on Waldenström’s Macroglobulinemia
Meletios A. Dimopoulos, MD, of the National and Kapodistrian University of Athens, discusses phase III findings on ibrutinib/rituximab vs placebo/rituximab in Waldenström’s macrogl...
Nathan Hale Fowler, MD, and Julie M. Vose, MD, MBA, on Follicular Lymphoma: Results From the RELEVANCE Trial
Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, and Nathan Hale Fowler, MD, of The University of Texas MD Anderson Cancer Center, discuss pha...
Arnaud Méjean, MD, PhD, on RCC: Results From the Carmena Trial
Arnaud Méjean, MD, PhD, of the Hôpital Européen Georges Pompidou, discusses his study’s potentially practice-changing finding that nephrectomy is no longer the standard of care for...
